P/E Ratio
Higher than 4% of Healthcare sector peers
Updated 1078h ago
Sector Performance
4th percentileKROS
6.3x
Sector Median
24.6x
Sector Avg
28.9x
Deep Analysis
Keros Therapeutics, Inc. (KROS) has a P/E Ratio of 6.3x as of May 2026.
This places KROS in the 4th percentile of the Healthcare sector, which has a median P/E Ratio of 24.6x and a sector average of 28.9x. KROS's P/E Ratio is 74.6% below the sector median, a significant divergence that warrants closer examination. In context: Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Frequently Asked Questions
What does the P/E Ratio tell investors about KROS?
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
How is the P/E Ratio calculated?
P/E Ratio is calculated as: Price / EPS.
How does KROS's P/E Ratio compare to its sector?
KROS's P/E Ratio of 6.3x compares to a Healthcare sector median of 24.6x, placing it in the 4th percentile.
Who are KROS's closest peers by P/E Ratio?
The closest Healthcare peers by P/E Ratio include: TMO (24.6x), AMGN (24.7x), BSX (25.8x), A (23.0x), AZN (27.0x).
The Formula
Price / EPS
Why It Matters
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Master KROS's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full KROS research report →KROS
6.3x
Sector Median
24.6x
Sector Avg
28.9x
How KROS's P/E Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.